Levothyroxine: A black swan? [BE/BA News]

posted by DavidManteigas – Portugal, 2017-11-27 17:53 (1518 d 11:12 ago) – Posting: # 18014
Views: 6,968

There isn't any biological background that might explain this issue? Or problems during manufacturing? This is really awkward... the CI and point estimate are far more "perfect" than I am used to see. In fact, in full replicate studies, I've seen reference drugs "performing" poorly when compared with single administrations of themselves... Is the dose-toxicity so sensible for this drug that event the narrower limits does not apply in this case? Did a quick search and haven't find any study reporting the dose-response of this drug

Complete thread:

Activity
 Admin contact
21,844 posts in 4,571 threads, 1,555 registered users;
online 3 (0 registered, 3 guests [including 2 identified bots]).
Forum time: Monday 05:05 CET (Europe/Vienna)

Do, or do not.
There is no ‘try’.    Yoda

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5